Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core Growth Allocation ETF (AOR) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares Core Growth Allocation ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares Core Growth Allocation ETF vs GeneDx Holdings Corp — how do they compare? iShares Core Growth Allocation ETF trades at $70.1, while GeneDx Holdings Corp trades at $82.37 (market cap $2.44B). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

AORWGS
52-Week High
$70.12$167.51
52-Week Low
$62.26$34.51
Market Cap
$2.44B
Sector
Technology
Enterprise Value
$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core Growth Allocation ETF

AOR, an iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% today. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF maintains a fixed 60/40 stock/bond allocation and rebalances semiannually with a low 0.20% fee. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.

The ETF offers diversified exposure but faces risks from equity-bond correlation shifts and competition from pure equity funds. Analyst sentiment is mixed, balancing its simplicity against historical lagging returns. Key catalysts include fee waivers until December 2026 and semiannual rebalancing, but investors should weigh its conservative allocation against growth objectives.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

About iShares Core Growth Allocation ETF

The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.

Read more on AOR

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS